The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2020 | Realigning MDS treatment goals
Mikkael Sekeres
• 5 Mar 2020
Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses the challenges in drug development in myelodysplastic syndromes (MDS) with respect to aligning trial endpoints for lower and higher risk patients with treatment goals meaningful to patients. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
